This funding opportunity supports the creation of a consortium dedicated to advancing the systematic identification, rigorous evaluation, validation, and harmonization of biomarkers critical to Type 1 Diabetes clinical research. It emphasizes harmonizing established assays like HbA1c and c-peptide and validating new biomarkers using advanced methodologies and metrology approaches across multiple laboratories to ensure reproducibility and reliability in clinical practice and research.
Eligible applicants include a wide range of organizations such as state and county governments, tribal governments and organizations, public housing authorities, nonprofits, institutions of higher education, for-profit organizations, small businesses, faith-based and community-based organizations, r
